TY - JOUR
T1 - Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis
AU - Mao, Serena P.H.
AU - Park, Minji
AU - Cabrera, Ramon M.
AU - Christin, John R.
AU - Karagiannis, George S.
AU - Oktay, Maja H.
AU - Zaiss, Dietmar M.W.
AU - Abrams, Scott I.
AU - Guo, Wenjun
AU - Condeelis, John S.
AU - Kenny, Paraic A.
AU - Segall, Jeffrey E.
N1 - Funding Information:
The authors would like to thank the support and advice from present and past members of the Segall, Cox, Condeelis, and Hodgson laboratories. This work was facilitated by the use of the P250 high-capacity slide scanner that was purchased with funding from National Institutes of Health. The authors would also like to thank the Albert Einstein Cancer Center for assisting our work conducted through the Genomics and Flow Cytometry Core Facilities.
Funding Information:
JES is the Betty and Sheldon Feinberg Senior Faculty Scholar in Cancer Research at the Albert Einstein College of Medicine. Funding was provided by National Institutes of Health grants CA100324 (JSC, JES), T32-GM007288 (SPHM, RMC), SIG grant 1S10OD019961-01, and the Albert Einstein Cancer Center (support grant P30CA013330). This work was also supported by the Integrated Imaging Program and the Gruss Lipper Biophotonics Center.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/10/26
Y1 - 2018/10/26
N2 - Background: Amphiregulin (AREG), a ligand of the epidermal growth factor receptor, is not only essential for proper mammary ductal development, but also associated with breast cancer proliferation and growth. In the absence of AREG, mammary ductal growth is stunted and fails to expand. Furthermore, suppression of AREG expression in estrogen receptor-positive breast tumor cells inhibits in-vitro and in-vivo growth. Methods: We crossed AREG-null (AREG-/-) mice with the murine luminal B breast cancer model, MMTV-PyMT (PyMT), to generate spontaneous breast tumors that lack AREG (AREG-/- PyMT). We evaluated tumor growth, cytokeratin-8 (K8)-positive luminal cells, cytokeratin-14 (K14)-positive myoepithelial cells, and expression of AREG, Ki67, and PyMT. Primary myoepithelial cells from nontumor-bearing AREG+/+ mice underwent fluorescence-activated cell sorting and were adapted to culture for in-vitro coculture studies with AT-3 cells, a cell line derived from C57Bl/6 PyMT mammary tumors. Results: Intriguingly, PyMT-induced lesions progress more rapidly in AREG-/- mice than in AREG+/+ mice. Quantification of K8+ luminal and K14+ myoepithelial cells in non-PyMT AREG-/- mammary glands showed fewer K14+ cells and a thinner myoepithelial layer. Study of AT-3 cells indicated that coculture with myoepithelial cells or exposure to AREG, epidermal growth factor, or basic fibroblast growth factor can suppress PyMT expression. Late-stage AREG-/- PyMT tumors are significantly less solid in structure, with more areas of papillary and cystic growth. Papillary areas appear to be both less proliferative and less necrotic. In The Cancer Genome Atlas database, luminal-B invasive papillary carcinomas have lower AREG expression than luminal B invasive ductal carcinomas. Conclusions: Our study has revealed a previously unknown role of AREG in myoepithelial cell development and PyMT expression. AREG expression is essential for proper myoepithelial coverage of mammary ducts. Both AREG and myoepithelial cells can suppress PyMT expression. We find that lower AREG expression is associated with invasive papillary breast cancer in both the MMTV-PyMT model and human breast cancer.
AB - Background: Amphiregulin (AREG), a ligand of the epidermal growth factor receptor, is not only essential for proper mammary ductal development, but also associated with breast cancer proliferation and growth. In the absence of AREG, mammary ductal growth is stunted and fails to expand. Furthermore, suppression of AREG expression in estrogen receptor-positive breast tumor cells inhibits in-vitro and in-vivo growth. Methods: We crossed AREG-null (AREG-/-) mice with the murine luminal B breast cancer model, MMTV-PyMT (PyMT), to generate spontaneous breast tumors that lack AREG (AREG-/- PyMT). We evaluated tumor growth, cytokeratin-8 (K8)-positive luminal cells, cytokeratin-14 (K14)-positive myoepithelial cells, and expression of AREG, Ki67, and PyMT. Primary myoepithelial cells from nontumor-bearing AREG+/+ mice underwent fluorescence-activated cell sorting and were adapted to culture for in-vitro coculture studies with AT-3 cells, a cell line derived from C57Bl/6 PyMT mammary tumors. Results: Intriguingly, PyMT-induced lesions progress more rapidly in AREG-/- mice than in AREG+/+ mice. Quantification of K8+ luminal and K14+ myoepithelial cells in non-PyMT AREG-/- mammary glands showed fewer K14+ cells and a thinner myoepithelial layer. Study of AT-3 cells indicated that coculture with myoepithelial cells or exposure to AREG, epidermal growth factor, or basic fibroblast growth factor can suppress PyMT expression. Late-stage AREG-/- PyMT tumors are significantly less solid in structure, with more areas of papillary and cystic growth. Papillary areas appear to be both less proliferative and less necrotic. In The Cancer Genome Atlas database, luminal-B invasive papillary carcinomas have lower AREG expression than luminal B invasive ductal carcinomas. Conclusions: Our study has revealed a previously unknown role of AREG in myoepithelial cell development and PyMT expression. AREG expression is essential for proper myoepithelial coverage of mammary ducts. Both AREG and myoepithelial cells can suppress PyMT expression. We find that lower AREG expression is associated with invasive papillary breast cancer in both the MMTV-PyMT model and human breast cancer.
KW - Amphiregulin
KW - Breast cancer
KW - MMTV-PyMT
KW - Mammary ductal development
UR - http://www.scopus.com/inward/record.url?scp=85055614066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055614066&partnerID=8YFLogxK
U2 - 10.1186/s13058-018-1057-0
DO - 10.1186/s13058-018-1057-0
M3 - Article
C2 - 30367629
AN - SCOPUS:85055614066
VL - 20
JO - Breast Cancer Research
JF - Breast Cancer Research
SN - 1465-5411
IS - 1
M1 - 131
ER -